Pharma Pricing Congress

Hot topics in pharma and orphan drugs

By Christina Poschen I attended this year’s Pharma Pricing and Market Access Conference in London with attendees across the pharmaceutical industry, payer and HTA bodies and patient representatives. While following the talks, panel discussions and roundtable debates, a few overarching key topics crystallised: –          Germany – AMNOG changes AMNOG, the German pharmaceutical law is regularly adapted to changes in the …

Image taken from Roche website http://www.roche.com/research_and_development/drawn_to_science/target_identification.htm

Rethinking Drug Discovery & Research Models in India

Drug discovery is a high risk, high return business. Despite the intrinsic risks, pharma companies continue to invest heavily in R&D to improve the quality of life of patients in needs of treatment. While capital is important in R&D outcomes, innovation-based organisations need to understand the best model to adopt to speed up the process in bringing discoveries to useful commercial …

Rising costs may not be a result of orphan drugs

Published Online: Sep 12,2016 Laurie Toich, Assistant Editor From Daraprim’s price rising 5556% by Turing Pharmaceuticals under the leadership of Martin Shkreli, to the most recent pricing scandal with Mylan’s EpiPen, Americans have been faced with high out-of-pocket costs for many prescription drugs. Government institutions, such as the US Centers for Medicare and Medicaid, have begun crafting novel ways to reduce …

5 minutes with Dr Subhadra Dravida, Founder and CEO of Transcell

Transcell Biologics is an innovative biotech company focuses in anti-cancer treatment, neurological ailments and autoimmune disorder. The innovative, stem cell based biotech company is based in Hyderabad, India. Ahead of this year’s BioPharma India 2016, we had the pleasure of grabbing a few minutes with its founder and CEO, Dr Subhadra Dravida.   What sparked the establishment of Transcell? We hope to translate stem cell …

The art of repositioning drugs: An interview with NovaLead Pharma’s Supreet Deshpande

Inventing a new drug requires huge financial commitment and it’s a lengthy process until it reaches patients in need. However, discovering a new application of an already clinically-approved drug saves you both time and allows you to fully utilise the power of your existing arsenal. Since the original drug application has a known function and toxicity, drug repurposing saves time and …

Algorics

Press-release: Mednet Solutions announces technology partnership with Algorics

May 19, 2016 Minnetonka, Minn. & Houston, Texas – MedNet Solutions, an innovative SaaS-based eClinical technology company that supports the entire spectrum of clinical research, and Algorics, a provider of cloud-based clinical analytics solutions and software for the global life sciences industry, today unveiled their strategic technology partnership designed to provide superior risk based monitoring (RBM) functionality to MedNet’s customers …

Anti-Microbial Resistance Congress 2016

It’s a Global Crisis: What the Review on Antimicrobial Resistance Wants to Do About AMR

   It’s a Global Crisis: What the Review on Anti-Microbial Resistance Wants to Do About AMR  After collaborating on a series of papers surrounding the growing health concern of drug-resistant infections, the Review on Antimicrobial Resistance released a final report this month, which outlined the steps and interventions this team of experts deems necessary for international progress. The facts and …

Abbot Laboratories Whitepaper

Whitepaper: Considerations in Purchasing a LIMS

Randy C. Hice | Abbot Laboratories Many scientific enterprises find themselves in need of a Laboratory Information Management System (LIMS) to replace an incumbent system, whether an existing commercial application, an amalgam of systems, or an in-house solution. Once the decision has been made, the selection and deployment of a new LIMS should move quickly and decisively. This white paper …

genomeweb whitepaper

Alternative Proposals for Lab Test Regulation

Are There Opportunities for Consensus? A GenomeWeb Report February 2016 Amid multiple proposals on LDT regulation, are there opportunities for consensus? By Turna Ray The lab industry entered 2016 in a staring contest with the US Food and Drug Administration that began two years ago when the agency released its draft guidance on regulating laboratory-developed tests (LDTs). During the course …